Caryn Gordon Mcdowell Sells 2,709 Shares of Cytokinetics, Inc. (CYTK) Stock

Cytokinetics, Inc. (NASDAQ:CYTK) insider Caryn Gordon Mcdowell sold 2,709 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $9.00, for a total transaction of $24,381.00. Following the completion of the transaction, the insider now directly owns 15,077 shares of the company’s stock, valued at approximately $135,693. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Caryn Gordon Mcdowell also recently made the following trade(s):

  • On Thursday, November 2nd, Caryn Gordon Mcdowell sold 4,260 shares of Cytokinetics stock. The shares were sold at an average price of $12.94, for a total transaction of $55,124.40.

Shares of Cytokinetics, Inc. (NASDAQ:CYTK) traded up $0.80 during mid-day trading on Friday, reaching $9.60. 420,697 shares of the company traded hands, compared to its average volume of 276,533. Cytokinetics, Inc. has a 1 year low of $7.00 and a 1 year high of $17.20. The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.04. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 62.64%. The firm had revenue of $6.18 million during the quarter, compared to analyst estimates of $5.35 million. research analysts anticipate that Cytokinetics, Inc. will post -2.4 EPS for the current year.

A number of hedge funds have recently modified their holdings of CYTK. Birchview Capital LP acquired a new position in Cytokinetics during the third quarter worth approximately $145,000. Piedmont Investment Advisors LLC acquired a new position in Cytokinetics during the third quarter worth approximately $159,000. BNP Paribas Arbitrage SA increased its position in Cytokinetics by 4,464.4% during the second quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 13,036 shares during the last quarter. SG Americas Securities LLC increased its position in Cytokinetics by 73.3% during the second quarter. SG Americas Securities LLC now owns 14,306 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 6,052 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Cytokinetics during the second quarter worth approximately $177,000. 73.61% of the stock is owned by hedge funds and other institutional investors.

CYTK has been the subject of a number of analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price objective on shares of Cytokinetics in a research report on Tuesday, September 26th. Seaport Global Securities reissued a “buy” rating and issued a $24.00 price objective on shares of Cytokinetics in a research report on Friday, October 6th. Morgan Stanley reissued an “overweight” rating and issued a $25.00 price objective (up previously from $24.00) on shares of Cytokinetics in a research report on Friday, October 6th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Cytokinetics in a research report on Friday, October 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Cytokinetics in a research report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $17.91.

COPYRIGHT VIOLATION WARNING: “Caryn Gordon Mcdowell Sells 2,709 Shares of Cytokinetics, Inc. (CYTK) Stock” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://sportsperspectives.com/2018/01/21/caryn-gordon-mcdowell-sells-2709-shares-of-cytokinetics-inc-cytk-stock.html.

About Cytokinetics

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply